Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.

Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.

Claudin18.2 is out, but the US big pharma opts in to a new project.